Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target.

Chen LY, Huang RL, Chan MWY, Yan PS, Huang TS, Wu RC, Suryo Rahmanto Y, Su PH, Weng YC, Chou JL, Chao TK, Wang YC, Shih IM, Lai HC.

J Pathol. 2019 Mar 18. doi: 10.1002/path.5266. [Epub ahead of print]

PMID:
30883733
2.

TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.

Duan H, Yan Z, Chen W, Wu Y, Han J, Guo H, Qiao J.

Gynecol Oncol. 2017 Nov;147(2):408-417. doi: 10.1016/j.ygyno.2017.08.010. Epub 2017 Aug 26.

PMID:
28851501
3.

TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions.

Su PH, Hsu YW, Huang RL, Chen LY, Chao TK, Liao CC, Chen CW, Wu TI, Mao SP, Balch C, Lai HC.

Cancer Lett. 2019 May 28;450:53-62. doi: 10.1016/j.canlet.2019.01.033. Epub 2019 Feb 13.

PMID:
30771438
4.

Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.

Ma Z, Wang X, He J, Xia J, Li Y.

PLoS One. 2017 Mar 29;12(3):e0174037. doi: 10.1371/journal.pone.0174037. eCollection 2017.

5.

Multiple Functions of Ten-eleven Translocation 1 during Tumorigenesis.

Tian YP, Zhu YM, Sun XH, Lai MD.

Chin Med J (Engl). 2016 Jul 20;129(14):1744-51. doi: 10.4103/0366-6999.185873. Review. Erratum in: Chin Med J (Engl). 2016 5th Nov;129(21):2646.

6.

TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.

Han X, Zhou Y, You Y, Lu J, Wang L, Hou H, Li J, Chen W, Zhao L, Li X.

Cell Biol Int. 2017 Apr;41(4):405-414. doi: 10.1002/cbin.10734. Epub 2017 Feb 16.

PMID:
28150354
7.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

8.

Effects of ten-eleven translocation 1 (Tet1) on DNA methylation and gene expression in chicken primordial germ cells.

Yu M, Li D, Cao W, Chen X, Du W.

Reprod Fertil Dev. 2018 Oct 4. doi: 10.1071/RD18145. [Epub ahead of print]

PMID:
30282572
9.

Ten-eleven translocation 1 (TET1) gene is a potential target of miR-21-5p in human colorectal cancer.

Cheng YW, Chou CJ, Yang PM.

Surg Oncol. 2018 Mar;27(1):76-81. doi: 10.1016/j.suronc.2017.12.004. Epub 2018 Jan 3.

PMID:
29549908
10.

Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.

Lai JI, Lai YC, Chen YC, Wang NK, Pan JN, Wang WS, Chang SC.

Cancer Gene Ther. 2017 Sep;24(9):373-380. doi: 10.1038/cgt.2017.26. Epub 2017 Aug 4.

PMID:
28776568
11.

Tet methylcytosine dioxygenase 1 promotes hypoxic gene induction and cell migration in colon cancer.

Ma L, Qi T, Wang S, Hao M, Sakhawat A, Liang T, Zhang L, Cong X, Huang Y.

J Cell Physiol. 2019 May;234(5):6286-6297. doi: 10.1002/jcp.27359. Epub 2018 Oct 26.

PMID:
30367454
12.

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.

Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K, Karpf AR.

Epigenetics. 2015;10(8):736-48. doi: 10.1080/15592294.2015.1062206.

13.

An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response.

Pinciroli P, Alberti C, Sensi M, Canevari S, Tomassetti A.

BMC Genomics. 2013 Jul 26;14:508. doi: 10.1186/1471-2164-14-508.

14.

TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression.

Pei YF, Tao R, Li JF, Su LP, Yu BQ, Wu XY, Yan M, Gu QL, Zhu ZG, Liu BY.

Oncotarget. 2016 May 24;7(21):31322-35. doi: 10.18632/oncotarget.8900.

15.

Immunity drives TET1 regulation in cancer through NF-κB.

Collignon E, Canale A, Al Wardi C, Bizet M, Calonne E, Dedeurwaerder S, Garaud S, Naveaux C, Barham W, Wilson A, Bouchat S, Hubert P, Van Lint C, Yull F, Sotiriou C, Willard-Gallo K, Noel A, Fuks F.

Sci Adv. 2018 Jun 20;4(6):eaap7309. doi: 10.1126/sciadv.aap7309. eCollection 2018 Jun.

16.

Tet1 facilitates hypoxia tolerance by stabilizing the HIF-α proteins independent of its methylcytosine dioxygenase activity.

Wang J, Zhang D, Du J, Zhou C, Li Z, Liu X, Ouyang G, Xiao W.

Nucleic Acids Res. 2017 Dec 15;45(22):12700-12714. doi: 10.1093/nar/gkx869.

17.

Melatonin impedes Tet1-dependent mGluR5 promoter demethylation to relieve pain.

Hsieh MC, Ho YC, Lai CY, Chou D, Wang HH, Chen GD, Lin TB, Peng HY.

J Pineal Res. 2017 Nov;63(4). doi: 10.1111/jpi.12436. Epub 2017 Aug 16.

PMID:
28718992
18.

TET1 regulates hypoxia-induced epithelial-mesenchymal transition by acting as a co-activator.

Tsai YP, Chen HF, Chen SY, Cheng WC, Wang HW, Shen ZJ, Song C, Teng SC, He C, Wu KJ.

Genome Biol. 2014 Dec 3;15(12):513. doi: 10.1186/s13059-014-0513-0.

19.

TET1 suppresses colon cancer proliferation by impairing β-catenin signal pathway.

Guo H, Zhu H, Zhang J, Wan B, Shen Z.

J Cell Biochem. 2019 Mar 1. doi: 10.1002/jcb.28522. [Epub ahead of print]

PMID:
30825236
20.

Hydroquinone increases 5-hydroxymethylcytosine formation through ten eleven translocation 1 (TET1) 5-methylcytosine dioxygenase.

Coulter JB, O'Driscoll CM, Bressler JP.

J Biol Chem. 2013 Oct 4;288(40):28792-800. doi: 10.1074/jbc.M113.491365. Epub 2013 Aug 12.

Supplemental Content

Support Center